SK's Cosca 25mg was first approved

Cosca 25mg was approved by the MFDS, and it is recommended as an initial dose for the elderly aged 75 or older

SK Chemical introduces generic for Losartan 25mg earlier than the original.

 

At one time, SK Chemicals had the experience of selling delegated generics of the original Cozaar, so it is drawing attention.

 

On the 14th, the MFDS approved SK Chemical's Cosca25mg (Losartan potassium).

 

Losartan potassium 25mg has been widely used, but it has not been approved so far.

 

Originally, only Cozaar (MSD) 50mg and Cozaar (MSD) 100mg, which are representative products, are available.

 

However, Cozaar (MSD) 25mg is used a lot in certain age groups as an initial dose.

 

For example, Cozaar 25mg is recommended as an initial dose for the elderly over 75 years, dialysis patients, children and adolescents over 6 years old, and patients with excessive blood pressure reduction.

 

Until now, Cozaar 25mg was not available, so Cozaar 50mg had to be split in half for the first dose prescription for that age group.

 

This is uncomfortable for pharmacists when dispensing them, and there is a risk of contamination.

 

The reason why this product is attracting attention is also that SK Chemicals sold entrusted generics through co-marketing with MSD in the past.

 

SK chemicals received products from MSD Korea from 2008 to 2012 and sold them under Cosca.

 

It was delegated generic for Cozaar.

 

However, the partnership was ended in 2012, and after that, through a change of license, the company's factory is producing generics that have been verified to be equivalent to the original.

 

It became a competitor to MSD.

 

Cozaar and Cosca are long-established drugs among ARB-based hypertension drugs.

 

Since many new drugs of the same series have been released so far, sales have decreased significantly compared to the initial release.

 

Based on UBIST last year, Cozaar recorded ₩27.9 billion and Cosca recorded ₩3.4 billion.

 

Before the release of generics, Cozaar exceeded ₩70 billion, and Cosca was the only generic over ₩10 billion.

 

It is noteworthy whether SK Chemicals will recover Losartan's past sales through this product.